Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study

Arthritis and Rheumatism

Volumn 44, Issue 7, 2001, Pages 1515-1524

  Van Ede, Annelies E ^a   Laan, Roland F J M ^a   Rood, Maarten J ^b   Huizinga, Tom W J ^b   Van De Laar, Mart A F J ^c   Van Denderen, Christiaan J ^d   Westgeest, Toon A A ^e   Romme, Ton C ^f   De Rooij, Dirk Jan R A M ^g   Jacobs, Marike J M ^a   De Boo, Theo M ^a   Van Der Wilt, Gert Jan ^a   Severens, Johan L ^a   Hartman, Margriet ^a   Krabbe, Paul F M ^a   Dijkmans, Ben A C ^h   Breedveld, Ferdinand C ^b   Van De Putte, Leo B A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d JAN VAN BREEMEN INSTITUTE   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

^f Zuiderziekenhuis   (Netherlands)

^g SINT MAARTENSKLINIEK   (Netherlands)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; FOLINIC ACID; LIVER ENZYME; METHOTREXATE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID; HEMATINICS; HUMANS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0034944211     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7     Document Type: Article

References (34)

1. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: A metaanalysis of published clinical trials
2. Methotrexate use in rheumatoid arthritis
3. Efficacy of low-dose methotrexate in rheumatoid arthritis
4. Methotrexate update
5. Methotrexate in rheumatoid arthritis: Toxic effects as the major factor in limiting long-term treatment
6. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients
7. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases
8. The mechanism of action of methotrexate
9. Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity
10. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: Results of a multicenter randomized, double-blind, placebo-controlled trial
11. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis
12. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: An 8 week randomized placebo controlled trial
13. Administration of folinic acid after low dose MTX in patients with RA
14. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients
15. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid
16. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis
17. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: A double-blind, placebo-controlled trial
18. 5 mg or 50 mg/week of folic acid supplementation does not alter the efficacy of methotrexate treated rheumatoid arthritis patients
19. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: A metaanalysis of randomized controlled trials
20. The use of folates concomitantly with low-dose pulse methotrexate
21. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
22. A toxicity index for comparison of side effects among different drugs
23. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
24. Evaluation of the Dutch Arthritis Impact Measurement Scales (DUTCH-AIMS) in patients with rheumatoid arthritis
25. Judging disease activity in clinical practice in rheumatoid arthritis: First step in the development of a disease activity score
26. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis
27. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria
28. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial
29. American College of Rheumatolooy preliminary definition of improvement in rheumatoid arthritis
30. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity
31. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
32. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis
33. Leflunomide versus methotrexate: A comparison of the European and American experience
34. Folic acid supplementation and methotrexate efficacy comment: Comment on articles by Schiff, Emery et al, and others